Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

B. Riley Securities Reiterates Buy on Cognition Therapeutics, Maintains $5 Price Target

Author: Benzinga Newsdesk | March 28, 2024 11:58am
B. Riley Securities analyst Mayank Mamtani reiterates Cognition Therapeutics (NASDAQ:CGTX) with a Buy and maintains $5 price target.

Posted In: CGTX

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist